✦ LIBER ✦

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

✍ Scribed by Paul La Rosée; Kara Johnson; Michael E O'Dwyer; Brian J Druker

Book ID: 114216854
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 216 KB
Volume: 30
Category: Article
ISSN: 0301-472X
DOI: 10.1016/s0301-472x(02)00836-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib Mesylate in the Treatment of Ch

Imatinib Mesylate in the Treatment of Chronic Myelogenous Leukemia

✍ Gautam Borthakur; Jorge E. Cortes 📂 Article 📅 2004 🏛 Carden Jennings Publishing 🌐 English ⚖ 108 KB

Long-term safety and efficacy of imatini

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study

✍ Philippe Rousselot; Pascale Cony-Makhoul; Franck Nicolini; François Xavier Mahon 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

Restoration of insulin sensitivity follo

Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML)

✍ Apostolos Tsapas; Efthymia Vlachaki; Maria Sarigianni; Filippos Klonizakis; Kons 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Insights from pre-clinical studies for n

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective

✍ La Rosée, P; O’Dwyer, M E; Druker, B J 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 132 KB

Significance of myelofibrosis in early c

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

✍ Hagop M. Kantarjian; Carlos E. Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND Myelofibrosis is associated historically with a poor prognosis in patients with chronic myelogenous leukemia (CML). Its significance in the recent era of effective therapy with imatinib mesylate is unknown. ## METHODS The current study evaluated the significance of the

Imatinib mesylate-sensitive blast crisis

Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases

✍ Takehiro Higashi; Junichi Tsukada; Chiaki Kato; Atsushi Iwashige; Takamitsu Mizo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views